[go: up one dir, main page]

ES2126620T3 - Retrovirus del grupo de los vih y su utilizacion. - Google Patents

Retrovirus del grupo de los vih y su utilizacion.

Info

Publication number
ES2126620T3
ES2126620T3 ES93116058T ES93116058T ES2126620T3 ES 2126620 T3 ES2126620 T3 ES 2126620T3 ES 93116058 T ES93116058 T ES 93116058T ES 93116058 T ES93116058 T ES 93116058T ES 2126620 T3 ES2126620 T3 ES 2126620T3
Authority
ES
Spain
Prior art keywords
retroviruses
immunological
hiv group
disease
ecacc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93116058T
Other languages
English (en)
Other versions
ES2126620T5 (es
Inventor
Lutz G Prof Dr Gurtler
Josef Dr Eberle
V Albrecht Dr Brunn
Stefan Dr Knapp
Hans-Peter Dr Hauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27435590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2126620(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4233646A external-priority patent/DE4233646C2/de
Priority claimed from DE4235718A external-priority patent/DE4235718A1/de
Priority claimed from DE4244541A external-priority patent/DE4244541A1/de
Priority claimed from DE4318186A external-priority patent/DE4318186C2/de
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Application granted granted Critical
Publication of ES2126620T3 publication Critical patent/ES2126620T3/es
Publication of ES2126620T5 publication Critical patent/ES2126620T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

SE DA A CONOCER UN NUEVO VIRUS DE DEBILITACION INMUNOLOGICA CON LA DESIGNACION MVP-5180/91, QUE FUE CONSIGNADO EN LA COLECCION EUROPEA DE CULTIVOS DE CELULAS ANIMALES (ECACC) CON EL NR. V 920 92 318. SE DAN A CONOCER ADEMAS LOS ANTIGENOS CARACTERISTICOS OBTENIBLES, QUE PUEDEN SER UTILIZADOS PARA LA COMPROBACION DE LOS ANTICUERPOS CONTRA RETROVIRUS, QUE ESTAN UNIDOS CON ENFERMEDADES DE DEBILITACION INMUNOLOGICA, ASI COMO LA SECUENCIA DE AMINOACIDOS Y DNS DEL VIRUS.
ES93116058T 1992-10-06 1993-10-05 Retrovirus del grupo de los vih y su utilizacion. Expired - Lifetime ES2126620T5 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE4233646A DE4233646C2 (de) 1992-10-06 1992-10-06 Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4233646 1992-10-06
DE4235718A DE4235718A1 (de) 1992-10-22 1992-10-22 Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4235718 1992-10-22
DE4244541A DE4244541A1 (de) 1992-12-30 1992-12-30 Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4244541 1992-12-30
DE4318186 1993-06-01
DE4318186A DE4318186C2 (de) 1993-06-01 1993-06-01 Retrovirus aus der HIV-Gruppe und dessen Verwendung

Publications (2)

Publication Number Publication Date
ES2126620T3 true ES2126620T3 (es) 1999-04-01
ES2126620T5 ES2126620T5 (es) 2010-05-21

Family

ID=27435590

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93116058T Expired - Lifetime ES2126620T5 (es) 1992-10-06 1993-10-05 Retrovirus del grupo de los vih y su utilizacion.

Country Status (9)

Country Link
US (12) US5770427A (es)
EP (2) EP0890642A3 (es)
JP (4) JP3277045B2 (es)
AT (1) ATE174382T1 (es)
AU (1) AU677225B2 (es)
CA (1) CA2107732C (es)
DE (1) DE59309207D1 (es)
DK (1) DK0591914T4 (es)
ES (1) ES2126620T5 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856088A (en) * 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6589734B1 (en) 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
JP3443809B2 (ja) 1992-03-06 2003-09-08 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 免疫学的に重要なエピトープに相当するペプチドの決定方法、及び免疫学的に重要なエピトープに相当するビオチニル化ペプチド又は抗体の決定のための方法におけるその利用、その調製方法及びそれを含む組成物
ES2126620T5 (es) * 1992-10-06 2010-05-21 Siemens Healthcare Diagnostics Products Gmbh Retrovirus del grupo de los vih y su utilizacion.
JP4108118B2 (ja) * 1993-03-26 2008-06-25 ジェン−プローブ・インコーポレイテッド ヒト・免疫不全ウイルス１型の検出
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
GB9410044D0 (en) * 1994-05-19 1994-07-06 Int Murex Tech Corp Assay
FR2726006B1 (fr) * 1994-10-20 1996-12-27 Pasteur Institut Sequences nucleotidiques codant des antigenes d'un retrovirus du type vih-1 groupe o
PT787191E (pt) 1994-10-20 2007-12-06 Pasteur Institut Sequências nucleotídicas de antigénios retroviraisde vih do tipo (ou sub-tipo) o
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
DE19505262C2 (de) * 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
US6548635B1 (en) 1995-02-16 2003-04-15 Dade Behring Marburg Gmbh Retrovirus from the HIV type O and its use (MVP-2901/94)
US5599662A (en) * 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
AU5100696A (en) * 1995-03-02 1996-09-18 Akzo Nobel N.V. Specific hiv-1 group o antigens
ES2220982T3 (es) * 1995-06-07 2004-12-16 Abbott Laboratories Peptidos destinados a la deteccion del vih-1.
US5733732A (en) * 1996-01-03 1998-03-31 University Of Iowa Research Foundation Methods for detecting primary adhalinopathy
WO1997027332A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
DE19644248A1 (de) * 1996-10-24 1998-04-30 Boehringer Mannheim Gmbh Primer und Probes zum Nachweis von HIV
WO1998044158A1 (en) * 1997-03-28 1998-10-08 Epitope, Inc. Simultaneous collection of dna and non-nucleic analytes from oral fluids
IL132166A0 (en) 1997-04-09 2001-03-19 Pasteur Sanofi Diagnostics Synthetic peptides which can be used in biological tests for the detection of infections due to group o hiv-1 viruses
US5922533A (en) * 1997-08-15 1999-07-13 Abbott Laboratories Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups
US6846905B2 (en) 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
DE19737442C2 (de) * 1997-08-22 1999-06-24 Olfert Landt Tib Molbiol Synth Proteinumhüllte Polyribonukleinsäuren, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
AU2345399A (en) * 1998-01-28 1999-08-16 Universal Health-Watch, Inc. Divergent hiv-1 peptides
CA2288869A1 (en) * 1998-03-04 1999-09-10 Mary Ann Childs Rapid confirmatory test for microbial infections
WO1999062945A2 (en) * 1998-06-05 1999-12-09 Peptide Solutions, Inc. Peptide antigens for detection of hiv, hcv and other microbial infections
CA2676762C (en) * 1998-11-30 2015-12-29 Ortho-Clinical Diagnostics, Inc. Peptides for the detection of hiv-1 group o
US6303293B1 (en) 1999-02-02 2001-10-16 Ortho-Clinical Diagnostics, Inc. Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof
EP1187939B9 (en) * 1999-07-09 2009-08-12 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification
WO2001047955A2 (en) * 1999-12-23 2001-07-05 Medical Research Council Improvements in or relating to immune responses to hiv
WO2001057245A2 (en) * 2000-02-04 2001-08-09 K.U.Leuven Research & Development Hiv-1 resistance assay
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2002125687A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法
EP2251442B9 (en) 2003-12-19 2012-04-25 Gen-Probe Incorporated Compositions, methods and kits for detecting the nucleic acids of HIV-1 and HIV-2
US7846676B2 (en) * 2004-07-19 2010-12-07 Cell Biosciences, Inc. Methods and devices for analyte detection
US7935479B2 (en) 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
US20060292558A1 (en) * 2004-07-19 2006-12-28 Cell Biosciences Inc. Methods and apparatus for protein assay diagnostics
EP1776581B1 (en) * 2004-07-19 2015-05-06 ProteinSimple Method for protein detection
WO2007035864A2 (en) 2005-09-20 2007-03-29 Cell Biosciences, Inc. Electrophoresis standards, methods and kits
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
US20080086118A1 (en) * 2006-05-17 2008-04-10 Applied Harmonics Corporation Apparatus and method for diode-pumped laser ablation of soft tissue
US20080017512A1 (en) * 2006-07-24 2008-01-24 Bordunov Andrei V Coatings for capillaries capable of capturing analytes
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
WO2009122592A1 (ja) * 2008-04-04 2009-10-08 国立大学法人琉球大学 常温保存可能な試薬を備えたウイルス抗原及びウイルス抗体の検出キット、並びにウイルス抗原及びウイルス抗体の検出方法
WO2009122591A1 (ja) * 2008-04-04 2009-10-08 国立大学法人琉球大学 ウイルス抗原及びウイルス抗体を一度に検出可能なウイルス抗原及びウイルス抗体の検出キット、並びにウイルス抗原及びウイルス抗体の検出方法
WO2009126517A2 (en) * 2008-04-09 2009-10-15 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1
JP2012532606A (ja) * 2009-07-07 2012-12-20 エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ ヒト免疫不全ウイルス１型（ｈｉｖ−１）の検出方法およびそのためのキット
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
WO2012153153A1 (en) 2011-05-11 2012-11-15 Diagon Kft. Procedure for rapid determination of viruses using nucleic acid-based molecular diagnostics, and a kit for this purpose
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9804079B2 (en) 2012-04-19 2017-10-31 ProteinSimple Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3286335A4 (en) * 2015-04-24 2018-10-17 The Johns Hopkins University Compositions and methods related to characterizing proviral reservoirs
CN116064923A (zh) * 2022-01-27 2023-05-05 圣湘生物科技股份有限公司 检测hiv-1的组合物、试剂盒、方法及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705612A (en) * 1984-10-18 1998-01-06 Institut Pasteur And Centre National De La Recherche Scientifique NEF peptide encoded by human immunodefiency virus type 1 (HIV-1)
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4803156A (en) * 1985-09-11 1989-02-07 New York Blood Center Peptide-beta-lactamase conjugates for enzyme-linked immunoassays
US6265149B1 (en) * 1986-01-22 2001-07-24 Institut Pasteur In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies
DE3760912D1 (en) * 1986-01-22 1989-12-07 Pasteur Institut Retrovirus of the type hiv-2 capable of inducing aids, and the antigenic and nucleic acid components thereof
US5079342A (en) * 1986-01-22 1992-01-07 Institut Pasteur Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5034511A (en) * 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
JP2777160B2 (ja) * 1987-04-16 1998-07-16 ジョンソン アンド ジョンソン Ｓｔｌｖ‐３関連ポリペプチド、診断系および検定法
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US5312737A (en) * 1988-03-11 1994-05-17 Abbott Laboratories CKS method of HCV protein synthesis
ES2072853T3 (es) * 1988-06-09 1995-08-01 Innogenetics Nv Retrovirus hiv-3 y su utilizacion.
US5223423A (en) * 1989-03-31 1993-06-29 United States Of America Characterization of replication competent human immunodeficiency type 2 proviral clone hiv-2sbl/isy
DE4002636A1 (de) * 1990-01-30 1991-08-01 Boehringer Mannheim Gmbh Expression von hiv1- und 2-polypeptiden und deren verwendung
US5013458A (en) * 1990-04-06 1991-05-07 Rdp Company Process and apparatus for pathogen reduction in waste
EP0554389B2 (en) * 1990-10-17 2002-08-14 The United States Of America Molecular clones of hiv-1 and uses thereof
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
ES2126620T5 (es) * 1992-10-06 2010-05-21 Siemens Healthcare Diagnostics Products Gmbh Retrovirus del grupo de los vih y su utilizacion.
US5304046A (en) * 1993-06-14 1994-04-19 Yang Gene Huang Fluid transport device
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung

Also Published As

Publication number Publication date
AU677225B2 (en) 1997-04-17
US20030166915A1 (en) 2003-09-04
JP2004187686A (ja) 2004-07-08
JP4029107B2 (ja) 2008-01-09
DE59309207D1 (de) 1999-01-21
US5840480A (en) 1998-11-24
JP4113318B2 (ja) 2008-07-09
DK0591914T4 (da) 2010-05-25
JP2006201185A (ja) 2006-08-03
EP0591914B1 (de) 1998-12-09
CA2107732C (en) 2003-04-08
US20030003443A1 (en) 2003-01-02
JPH06225760A (ja) 1994-08-16
ATE174382T1 (de) 1998-12-15
US20020155428A1 (en) 2002-10-24
US20020172939A1 (en) 2002-11-21
US5759770A (en) 1998-06-02
ES2126620T5 (es) 2010-05-21
JP3277045B2 (ja) 2002-04-22
US6528626B2 (en) 2003-03-04
US5770427A (en) 1998-06-23
US20070264627A1 (en) 2007-11-15
EP0890642A3 (de) 2000-09-13
US6531137B2 (en) 2003-03-11
EP0591914B2 (de) 2010-02-10
JP2000312592A (ja) 2000-11-14
US6277561B1 (en) 2001-08-21
US6551824B2 (en) 2003-04-22
EP0591914A2 (de) 1994-04-13
EP0591914A3 (en) 1994-08-10
US6773915B2 (en) 2004-08-10
AU4880093A (en) 1994-04-21
US20050053920A1 (en) 2005-03-10
EP0890642A2 (de) 1999-01-13
US20030003442A1 (en) 2003-01-02
CA2107732A1 (en) 1994-04-07
JP3854604B2 (ja) 2006-12-06
US20070105219A1 (en) 2007-05-10
US6531587B2 (en) 2003-03-11
DK0591914T3 (da) 1999-08-16

Similar Documents

Publication Publication Date Title
ES2126620T3 (es) Retrovirus del grupo de los vih y su utilizacion.
Weinhold et al. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals
ES2124922T3 (es) Peptidos derivados de un retrovirus del grupo hiv y su uso.
Chardonnens et al. Induction of skin allograft tolerance during metamorphosis of the toad Xenopus laevis: a possible model for studying generation of self tolerance to histocompatibility antigens
BR9912177A (pt) Epìtopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptìdeo sintéticos
ES2079638T3 (es) Anticuerpos humanizados.
ES2118084T3 (es) Anticuerpos anti-icam-1 quimericos humanizados, metodos de preparacion y su uso.
ES2055785T3 (es) Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2100174T3 (es) Nuevos anticuerpos reactivos con carcinomas humanos.
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
PE43298A1 (es) Genes sinteticos de vih
ES2065863T3 (es) Analisis para la deteccion de virus de la hepatitis c.
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
ES2067866T3 (es) Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.
WO1991004273A3 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
Kristensen et al. Contribution of NK cell education to both direct and anti-HIV-1 antibody-dependent NK cell functions
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
Kleemann et al. Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation
Daher et al. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
ES2056075T3 (es) Anticuerpos monoclonales para regiones especificas antigenicas del virus de inmunodeficiencia humana y procedimientos para su uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 591914

Country of ref document: ES